The optimal systemic treatment for pulmonary large-cell neuroendocrine carcinoma (LCNEC) is still under debate. Previous studies showed that LCNEC with different genomic characteristics might respond differently to different chemotherapy regimens. In this study, we sought to investigate genomic subtyping using cell-free DNA (cfDNA) analysis in advanced LCNEC and assess its potential prognostic and predictive value.
Tumor DNA and cfDNA from 63 patients with LCNEC were analyzed by target-captured sequencing. Survival and response analyses were applied to 54 patients with advanced stage incurable disease who received first-line chemotherapy.
The mutation landscape of frequently mutated cancer genes in LCNEC from cfDNA closely resembled that from tumor DNA, which led to a 90% concordance in genomic subtyping. The 63 patients with LCNEC were classified into small-cell lung cancer (SCLC)-like and non–small cell lung cancer (NSCLC)-like LCNEC based on corresponding genomic features derived from tumor DNA and/or cfDNA. Overall, patients with SCLC-like LCNEC had a shorter overall survival than those with NSCLC-like LCNEC despite higher response rate (RR) to chemotherapy. Furthermore, treatment with etoposide-platinum was associated with superior response and survival in SCLC-like LCNEC compared with pemetrexed-platinum and gemcitabine/taxane-platinum doublets, while treatment with gemcitabine/taxane-platinum led to a shorter survival compared with etoposide-platinum or pemetrexed-platinum in patients with NSCLC-like LCNEC.
Genomic subtyping has potential in prognostication and therapeutic decision-making for patients with LCNEC and cfDNA analysis may be a reliable alternative for genomic profiling of LCNEC.
Large-cell neuroendocrine carcinomas (LCNEC) constitute a group of aggressive lung cancers with poor prognosis. The optimal chemotherapy regimen for advanced LCNEC is still under debate. Genomic subtyping may help to facilitate choosing chemotherapy regimens. However, tumor tissues are often inadequate for genomic profiling. Our results showed that mutation landscape from cfDNA closely resembled that from tumor DNA, which led to a 90% concordance in genomic subtyping. Furthermore, patients with small-cell lung cancer–like LCNEC and patients with non–small cell lung cancer-like LCNEC based on genomic subtyping had different survival and treatment response to different chemotherapy regimens. These results supported the potential of genomic subtyping in prognostication and therapeutic decision-making for patients with LCNEC and indicated that cfDNA analysis may be a reliable alternative for genomic profiling of LCNEC.
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine malignancy that accounts for about 1%–3% of all lung cancers (1, 2). LCNEC tumors constitute a group of aggressive lung cancers characterized by high proliferation rate and poor prognosis (3, 4). As a group of molecularly and biologically heterogeneous diseases, LCNEC tumors share many similar molecular and histologic features with small-cell lung cancer (SCLC; refs. 5–7), as well as with non–small cell lung cancer (NSCLC; ref. 8). Management of localized LCNEC tumors differs from that for SCLC in that surgical resection is considered standard for stage I and II diseases, similar to NSCLC, while surgery is only considered for node-negative stage I–IIA (T1–2, N0, and M0) SCLC. For stages III and IV, treatment generally follows recommendations for SCLC, but the optimal chemotherapy regimen is still under debate. While some studies suggested that LCNEC should be treated as NSCLC, others have suggested LCNEC may respond better to etoposide-platinum, used in treating SCLC (9).
Previous pioneering studies indicate that LCNEC can be divided into different genomic subtypes, with similarities to either SCLC or NSCLC (8, 10). More recently, Derks and colleagues reported that patients with LCNEC harboring wild-type RB1 had improved progression-free survival (PFS) and overall survival (OS) when treated with gemcitabine or taxane partnered with platinum compared with etoposide with platinum (11). These interesting data suggested that genomic subtyping might have the potential to facilitate choosing chemotherapy regimens. However, although tissue sequencing remains the gold standard for genomic profiling, tumor tissues are often inadequate for next-generation sequencing (NGS) after histologic diagnosis in advanced LCNEC. Recently, cell-free DNA (cfDNA) analysis has demonstrated great potential in genomic profiling and identifying targetable genomic aberrations (12–14), disease monitoring (15–17), and detection of minimal residual disease (18, 19) across different cancer types. In this study, we sought to investigate whether cfDNA analysis could serve as a reliable alternative for genomic subtyping of LCNEC.
Materials and Methods
Patients and sample collection
Patients who were diagnosed with LCNEC and treated with chemotherapy at Peking University Cancer Hospital (Beijing, China, referred as BJ-Cohort hereafter) or the University of Texas MD Anderson Cancer Center (Houston, TX, referred as MDA-Cohort hereafter) from January 2007 to May 2018 were enrolled. The patients of MDA-Cohort were from GEMINI database, an MD Anderson Moon Shot Program–supported registry study. The study was performed in accordance with the ethical guidelines of the Declaration of Helsinki and approved by the Institutional Review Boards of the Peking University Cancer Hospital or University of Texas MD Anderson Cancer Center, and all patients signed informed consent.
The pathologic diagnosis was reviewed and confirmed by an independent pulmonary pathologists according to the 4th edition of the World Health Organization Classification of Lung Tumors (20) and tumors with histologic components other than LCNEC were excluded, and neuroendocrine features were confirmed by at least one of the following neuroendocrine markers: CD56, chromogranin A, or Synaptophysin in >10% of tumor cells. Tumor specimens and peripheral blood samples were collected for NGS analysis. Forty-one of 45 tumor tissues and 37 of 41 plasma samples were collected prior to initiation of any therapy. Tissue samples from 4 patients (MDA20, MDA23, MDA27, and MDA30 in MDA-Cohort) and blood samples from 4 patients (A03, A09, and A11 in BJ-Cohort and MDA21 in MDA-Cohort) were collected after chemotherapy. All samples were procured before targeted therapy when applicable. Tissue specimens containing a minimum of 50% tumor cells were used for NGS analysis.
Sample processing and NGS from BJ-Cohort
Tumor DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) specimens. Matched peripheral blood sample was collected in EDTA Vacutainer tubes (BD Diagnostics) and processed within 3 hours of receiving. Plasma was separated by centrifugation at 2,500 × g for 10 minutes, transferred to microcentrifuge tubes, and centrifuged at 16,000 × g for 10 minutes to remove remaining cell debris. Peripheral blood lymphocytes (PBL) from the first centrifugation were used for the extraction of germline genomic DNA as normal control. PBL DNA and tumor tissue DNA were extracted using the DNeasy Blood & Tissue Kit (Qiagen). cfDNA was isolated from 0.5–2.0 mL plasma using QIAamp Circulating Nucleic Acid Kit (Qiagen).
PBL or tissue DNA was sheared to 300-bp fragments with a Covaris S2 ultrasonicator followed by the Indexed Illumina NGS library preparation using Illumina TruSeq DNA Library Preparation Kit (Illumina) following the manufacture's instruction. Sequencing libraries were prepared for cfDNA using the KAPA DNA Library Preparation Kit (KapaBiosystems). Libraries were hybridized to custom-designed biotinylated oligonucleotide probes (Roche NimbleGen) covering genes as indicated in Supplementary Table S1. DNA sequencing was performed using the HiSeq 3000 Sequencing System with 2 × 151-bp paired-end reads according to the manufacturer's recommendations using HiSeq 3000/4000 PE Cluster Generation Kit and HiSeq 3000/4000 SBS Kit (Illumina).
Terminal adaptor sequences and low-quality reads were removed before Burrows-Wheeler Aligner (version 0.7.12-r1039) was employed to align the clean reads to the reference human genome (hg19). Picard (version 1.98) was used to mark PCR duplicates. Realignment and recalibration were performed using GATK (version 3.4-46-gbc02625). Single-nucleotide variants (SNV) were called using MuTect (version 1.1.4) and NChot, a software developed in-house to review hotspot variants (21). Small insertions and deletions (Indel) were called by GATK. Somatic copy-number alterations were identified with CONTRA (v2.0.8). Significant copy number variation was expressed as the ratio of adjusted depth between cfDNA and control gDNA. The final candidate variants were all manually verified in the integrative genomics viewer.
Sample processing and NGS from MDA-Cohort
Tumor DNA from MDA-Cohort was applied to a Clinical Laboratory Improvement Amendments–certified institutional NGS test as described previously (22). Briefly, 10–20 ng DNA from each FFPE specimen was analyzed with the Oncomine Cancer Panel (Thermo Fisher Scientific) at an average amplicon depth of at least 100 ×, providing critical exon coverage of 50–146 genes for the detection of SNVs, indels, and copy number amplifications (ref. 23; Supplementary Table S2). One sample, MDA24, was tested for FoundationOne that covered 315 cancer genes (24).
cfDNA was analyzed using Guardant360 Assay (Guardant Health), a proprietary cfDNA NGS assay that detects SNVs of 70 genes, as well as selected actionable or informative copy number aberrations, indels, and fusions (Supplementary Table S2). cfDNA was extracted from the entire plasma aliquot prepared from a single 10 mL Streck Cell-Free DNA BCT (Streck, Inc.) and QIAmp Circulating Nucleic Acid Kit (Qiagen, Inc.). Five to 30 ng of extracted cfDNA was used to prepare sequencing libraries, which were then enriched by hybrid capture (Agilent Technologies, Inc.), pooled, and sequenced by paired-end sequencing of 160–170 base pair DNA strands with average coverage of 8,000 × to 15,000 × (NextSeq 500 and/or HiSeq 2500, Illumina, Inc.). Germline variants were quantitatively excluded as described previously (25).
PyClone (26) was applied to mutations from 20 patient samples from Peking University Cancer Hospital with paired tumor DNA and cfDNA to infer the subclonal architecture of these specimens. Briefly, PyClone was run with 20,000 iterations and default parameters. The copy number information of each SNV was used as input for PyClone analysis (15, 27), and variants were clustered as described previously (26). Clonal mutations were defined as variants in the cluster with greatest mean cancer cell fraction, otherwise subclonal (26).
Tumor responses (CR, complete remission; PR, partial response; SD, stable disease; and progressive disease) were evaluated according to the RECIST version 1.1 (28). Overall response rate was defined as total number of responders, including complete and partial responders, divided by the response-evaluable patients. PFS was defined as the time from the starting day of first-line chemotherapy to the first day of documented disease progression or death from any cause. Patients without progressive disease at the time of analysis were censored at the time of the last follow-up. Survival curves were generated using the Kaplan–Meier method, and the log-rank test was used to compare the survival curves. The clinicopathologic characteristics and response rates (RR) of chemotherapy were compared between the two groups using χ2 tests. Differences in categorical variables between two groups for statistical significance were evaluated using the c2 test or Fisher exact test. All multivariate statistical analyses were performed with SPSS (v.23.0; IBM), and survival analyses were performed with GraphPad Prism (v. 6.0; GraphPad Software) software. Statistical significance was defined as a two-sided P < 0.05. The group including less than five samples was not used to do statistical analyses. Survival and response analyses were only applied to patients with advanced disease (stage IIIB and IV) who received first-line chemotherapy.
In this retrospective study, a total of 63 patients with LCNEC were enrolled including 44 patients from Peking University Cancer Hospital (BJ-Cohort) and 19 patients from University of Texas MD Anderson Cancer Center (MDA-Cohort). Among these patients, 54 of 63 patients with incurable stage IIIB or IV LCNEC received first-line chemotherapy (Table 1). The chemotherapy regimens include: etoposide-platinum commonly used for SCLC (hereafter referred as SCLC-PE); pemetrexed with platinum usually used for nonsquamous cell NSCLC (hereafter referred as NSCLC-PEM); and gemcitabine, docetaxel, or paclitaxel with platinum commonly used for NSCLC and sometimes in SCLC (hereafter referred as NSCLC-GEM/TAX; Supplementary Table S3).
|Characteristics .||.||Patients (n = 63) .|
|Smoking status||Smoker||70% (44)|
|Stage IIIB or IV diseases; received first-line chemotherapy (n = 54)||NSCLC-GEM/TAX||14|
|Characteristics .||.||Patients (n = 63) .|
|Smoking status||Smoker||70% (44)|
|Stage IIIB or IV diseases; received first-line chemotherapy (n = 54)||NSCLC-GEM/TAX||14|
Mutational landscape of LCNEC
To depict the mutation landscape of LCNEC tumors, we first analyzed the mutations from tumor DNA of 28 patients from BJ-Cohort, which were subjected to NGS of a panel of 179 known cancer genes (Supplementary Table S1). The average sequencing depth was 919 × (103 × to 3,008 ×). Mutations were identified in all 28 tumors for a total of 205 somatic variants (7.4 variants per sample on average), including 146 missense, 20 nonsense, seven splice sites, 13 frame-shift mutations, three deletions, one insertion, one gene fusion, four copy number gains, and 10 copy number losses with a mean nonsynonymous mutation burden of 13.6 mutations/megabase (Supplementary Table S4), comparable with previous report (10). Commonly altered genes in these LCNEC tumors included TP53 (n = 21, 75%), RB1 (n = 9, 32.1%), SMARCA4 (n = 6, 21.4%), NOTCH1 (n = 5, 17.9%), KEAP1 (n = 5, 17.9%), etc. In addition, KRAS, EGFR, and CDKN2A mutations were found in 4 patients and STK11 mutation or loss was detected in 2 patients (Fig. 1A; Supplementary Table S4).
There were 32 cancer genes covered by both cancer gene panels used in sequencing tumor DNA specimens from MDA-Cohort and BJ-Cohort (Supplementary Table S5). Because smaller gene panels were utilized and fewer patients were tested, we did not attempt to depict the genomic landscape of LCNEC tumors from MDA-Cohort. Nevertheless, the two most important cancer genes for LCNEC TP53 (76% in MDA-Cohort vs. 75% in BJ-Cohort) and RB1 (29% in MDA-Cohort vs. 32% in BJ-Cohort) had similar mutation rates compared with BJ-Cohort. On the other hand, mutations of STK11 were more common in MDA-Cohort (35% in MDA-Cohort vs. 7% in BJ-Cohort; P = 0.04) that may reflect the ethnic and etiologic differences between these two patient populations.
cfDNA analysis may be a potentially promising alternative for genomic profiling of LCNEC
To investigate the feasibility of genomic profiling of LCNEC using cfDNA, cfDNA from 39 patients from BJ-Cohort was subjected to NGS of the same 179 cancer genes at an average sequencing depth of 1,325 × (range 447 × to 2,457 ×). A total of 182 somatic variants were identified (ranging from 5 to 38 per sample) in 36 of 39 (92.3%) cfDNA samples including 171 SNVs/indels, four copy number gains, and seven copy number losses with an average of 9.6 mutations/megabase, which was slightly lower than that from tumor DNA. As shown in Fig. 1B; Supplementary Table S6, the overall mutational landscape derived from cfDNA was similar to that from tumor DNA. TP53 (n = 24, 66.7%), RB1 (n = 7, 19.4%), NF1 (N = 7, 19.4%), SMARCA4 (n = 6, 16.7%), EGFR (n = 5, 13.9%), KEAP1 (n = 5, 13.9%), and NOTCH1 (n = 5, 13.9%) were the most frequently mutated genes in cfDNA in this patient cohort. In addition, somatic alterations in KRAS, ATM, BRCA1, or CDKN2A were detected in 4 of 39 patients and mutations in STK11 or BRCA2 were identified in 3 patients. No mutations were detected in cfDNA samples of A03, A09, and A11.
To further assess the reliability of genomic profiling of LCNEC tumors using cfDNA, we next analyzed the 23 patients from BJ-Cohort who had paired tumor and cfDNA subjected to NGS of the same panel of 179 cancer genes. Somatic variants were identified in all 23 tumor DNA and 20 of the 23 cfDNA specimens (no variants were detected from cfDNA samples of A03, A09, and A11 as described above; Fig. 2). Interestingly, only 19% of tumor DNA–specific mutations and 31% of cfDNA-specific mutations were clonal, while 56% of mutations shared by tumor DNA and cfDNA were clonal, indicating the substantial genomic heterogeneity of LCNEC tumors. Importantly, the concordance rate for the most frequently mutated genes such as RB1, TP53, PTEN, FGFR1, and FGFR4 was 90% (18/20), 85% (17/20), 95% (19/20), 90% (18/20), and 95% (19/20), respectively, suggesting cfDNA sequencing may be a promising alternative for genomic profiling of advanced LCNEC tumors, particularly for the frequently mutated cancer genes.
Genomic subtyping of LCNEC
Several pioneer studies (8, 10, 11) have demonstrated that mutations in RB1 and TP53 are critical biomarkers for subclassification of LCNEC. We next classified patients of BJ-Cohort into two groups based on the mutational status of RB1 and TP53 (criterion 1). Considering the high concordance between tumor DNA and cfDNA profiling particularly in the most frequently mutated genes, NGS data from tumor DNA and cfDNA was merged for subsequent genomic subtyping analyses. Patients with mutations or copy number loss in both RB1 and TP53 were classified as SCLC-like LCNEC and patients without RB1+TP53 coalterations were classified as NSCLC-like LCNEC. On the basis of this criterion, 20 of the 28 patients from BJ-Cohort were classified as NSCLC-like LCNEC and 8 patients as SCLC-like LCNEC. From the 36 patients with mutations detected from cfDNA, 28 patients were classified as NSCLC-like LCNEC and 8 as SCLC-like LCNEC. Importantly, among the 20 patients who had somatic variants detected in paired tumor DNA and cfDNA, the genomic classification based on tumor DNA or cfDNA was concordant in 90% (18/20) of patients (Supplementary Table S7), once again highlighting the reliability of cfDNA analysis for genomic subtyping of LCNEC. Similarly, based on this criterion, 15 patients from MDA-Cohort were classified as NSCLC-like LCNEC and 4 patients as SCLC-like LCNEC.
Genomic subtyping is associated with survival and chemotherapy response
We next sought to investigate the impact of genomic characteristics on clinical outcome of patients with LCNEC. On the basis of the presence of coalterations in TP53 and RB1 (criterion 1), 15 of 63 patients were classified as SCLC-like LCNEC and 48 as NSCLC-like LCNEC. Interestingly, the SCLC-like LCNEC tumors displayed significantly higher level of Ki67, a marker for cell proliferation, than NSCLC-like tumors (P < 0.05; Supplementary Fig. S1). Fifty-four of the 63 patients with incurable stage IIIB and IV LCNEC received platinum-based chemotherapy as first-line treatment. The overall response rate (RR = CR + PR) was 46.7% (7/15) in patients with SCLC-like LCNEC and 25.6% (10/39) in patients with NSCLC-like LCNEC. However, despite higher RR, the OS of patients with SCLC-like LCNEC appeared to be shorter than those with NSCLC-like LCNEC although it did not reach statistical significance (median 9.8 months vs. 14.4 months; P = 0.18).
Next, we investigated whether genomic subtyping is associated with response to different chemotherapy regimens as reported previously (10, 11). In SCLC-like LCNEC, the disease control rate (DCR = CR + PR + SD) and RR to SCLC-PE regimen were significantly higher than those to the NSCLC-PEM regimen (100% vs. 20%; P = 0.007 for DCR and 75% vs. 0%; P = 0.02 for RR, respectively; Fig. 3A). In addition, the PFS of patients treated with SCLC-PE was significantly longer than patients treated with NSCLC-PEM (8.3 vs. 2.4 months; P = 0.002; Fig. 4A). The OS of patients treated with SCLC-PE regimen also appeared to be longer than those treated with NSCLC-PEM although the difference was not significant (9.7 vs. 4.1 months; P = 0.6; Fig. 4B).
For the NSCLC-like LCNEC, on the other hand, neither DCR nor RR was significantly different between patients treated with three different chemotherapy regimens (Fig. 3B). However, compared with NSCLC-GEM/TAX regimen, SCLC-PE was associated with significantly longer PFS (median 5.5 vs. 2.5 months; P = 0.045; Fig. 4C) and longer OS with borderline significance (median 19.6 vs. 9.4 months; P = 0.07; Fig. 4D).
Optimized genomic subtyping
Compared with previous studies (10, 11), SCLC-like LCNEC seemed be underrepresented in our cohorts: 24% (15/63) compared with 42% (18/43) in MSKCC cohort (10). We next explored whether we could further classify NSCLC-like LCNEC by analyzing additional genomic aberrations that were more frequently associated with SCLC including PTEN loss/mutation, FGFR4/FGFR1 mutation/amplification, and TP53 loss (29–31). We therefore classified LCNEC harboring any of these alterations: RB1 mutation or loss, PTEN loss/mutation, FGFR1/FGFR4 mutation/amplification, and TP53 loss, as “SCLC-like” tumors, otherwise as NSCLC-like (criterion 2). With these criteria, 27 patients were classified as SCLC-like and 36 as “NSCLC-like.” Once again, despite higher RR to chemotherapies in SCLC-like LCNEC compared with NSCLC-like LCNEC (41% vs. 22%), patients with SCLC-like LCNEC had shorter OS than patients with NSCLC-like LCNEC although the difference was not significant (10.3 vs. 14.4 months; P = 0.32).
For SCLC-like LCNEC based on criterion 2, SCLC-PE once again demonstrated superiority compared with NSCLC-PEM with regards to DCR (92% vs. 14%; P = 0.002), RR (67% vs. 0%; P = 0.01; Fig. 3C), PFS (median 8.3 vs. 2.3 months; P = 0.0002; Fig. 4E), and OS (median 10.3 vs. 5 months; P = 0.07; Fig. 4F). In addition, NSCLC-GEM/TAX also appeared to be superior to NSCLC-PEM with higher DCR (88% vs. 14%; P = 0.01) and RR (38% vs. 0%; P = 0.2; Fig. 3C), as well as longer PFS (median 5.9 vs. 2.3 months; P = 0.007; Fig. 4E) and OS (median 23.9 vs. 5 months; P = 0.06; Fig. 4F).
In the NSCLC-like LCNEC based on criterion 2, no differences were observed in the DCR or RR for different regimens (Fig. 3D). However, compared with NSCLC-GEM/TAX, SCLC-PE was associated with significantly longer PFS (median 4.1 vs. 1.9 months; P = 0.03) and borderline significantly longer OS (median 16 vs. 7.3 months; P = 0.08). NSCLC-PEM also appeared to be superior to NSCLC-GEM/TAX in PFS (median 4 vs. 1.9 months; P = 0.07) and OS (median 29.8 vs. 7.3 months; P = 0.22) but the difference did not reach statistical significance (Fig. 4G and H).
Combining NSCLC-regimen treatment subgroups
Given the small sample size in this study, we combined NSCLC-GEM/TAX and NSCLC-PEM subgroups and redid the analyses. As shown in the Supplementary Fig. S2, SCLC-PE was associated with significantly longer PFS than NSCLC regimens (GEM/TAX or PEM) in SCLC-like LCNEC patients based on either criterion 1 (median 8.3 vs. 3.0 months; P = 0.0013; Supplementary Fig. S2A) or criterion 2 (median 8.3 vs. 3.0 months; P = 0.0032; Supplementary Fig. S2E), but OS did not seem to be different (Supplementary Fig. S2C and S2G). For patients with NSCLC-like LCNEC, SCLC-PE also appeared to be superior or at least equivalent to NSCLC regimens for both PFS and OS (Supplementary Fig. S2B, S2D, S2F, and S2H), suggesting that SCLC-PE might be the most effective regimen for the majority of patients with LCNEC.
Sensitive gene mutations indicating target therapy
In this cohort of LCNEC, targetable genomic aberrations were detected in 5 patients including EGFR L858R mutation in patients A04, A21, and A35, an EGFR T790M mutation in patient A15, and EML4-ALK fusion in patient A11 from BJ-Cohort. All these 5 patients were wild-type for RB1. Patients A04, A21, and A35 carrying EGFR L858R mutation received EGFR tyrosine kinase inhibitor gefitinib or erlotinib at the time of disease progression after chemotherapy and all achieved a PR, while patient A15 with EGFR T790M and patient A11 with EML4-ALK fusion have not received target therapy agents yet. Of particular interest, the classic targetable mutations in EGFR or ALK were only detected in patients from BJ-Cohort, but not from MDA-Cohort. Similarly, such mutations were rarely reported in Caucasian patients (32–34). Taken together, these results implied the potential ethnic and etiologic differences between Caucasian and Asian patients and suggested genomic profiling is warranted at least for Asian patients with advanced LCNEC to potentially identify underappreciated treatment options.
Currently, the diagnosis of LCNEC is largely dependent on histology and IHC assessment, which may not always accurately reflect the true tumor biology. Genomic features may provide additional information for the clinical and biological behaviors of LCNEC. TP53 and RB1 were the most commonly altered cancer genes in LCNEC. The prevalence of genomic alterations was reported to be as high as 71% to 92% for TP53 and 26% to 47% for RB1 (8, 10, 11, 35). In addition to point mutations, inactivation of RB1 can occur via large chromosomal losses, which are poorly detected by NGS. IHC may potentially capture those LCNEC with large chromosomal loss–mediated RB1 loss (8). We attempted to test RB1 by IHC, however, were unsuccessful due to depletion of specimens, once again highlighting this challenge in studying advanced LCNEC. Nevertheless, the frequency of genomic alterations in TP53 (81% in MDA-Cohort and 75% in BJ-Cohort) and RB1 (25% in MDA-Cohort and 32% in BJ-Cohort) in this study was comparable with previous studies (8, 10, 11, 35).
A practical challenge for genomic profiling in advanced LCNEC is the insufficient tissue for NGS-based assays. In this study, we demonstrated that the mutation landscape of the most frequently mutated cancer genes in LCNEC derived from cfDNA resembled that from tumor DNA, which led to a 90% concordance in genomic subtyping of LCNEC suggesting that cfDNA sequencing may be a reliable modality for detecting somatic mutations and defining genomic subtypes of LCNEC. Furthermore, cfDNA sequencing is noninvasive and “real-time,” which makes it an ideal tool for monitoring response and investigating genomic evolution of LCNEC over time, particularly during treatment. There were 3 patients in our cohort who had mutations detected in tumors, but not in cfDNA. Interestingly, all 3 patients received chemotherapy and achieved a PR before blood collection. Therefore, the “failure to detect mutations from cfDNA” may have reflected treatment response.
Pioneer studies have demonstrated that genomic features may be able to classify LCNEC into different molecular subtypes that may be associated with distinct response to different chemotherapy regimens (8, 10, 11, 35). Using previously defined criteria of coalterations of RB1 and TP53, or our extended criteria, the OS appeared to be shorter in patients with SCLC-like LCNEC tumors despite higher RR to chemotherapy, which is reminiscent of classic SCLC and NSCLC. In addition, chemotherapy with etoposide-platinum commonly used for treating SCLC demonstrated superiority compared with NSCLC regimens. These data suggest that a proportion of LCNEC may truly resemble classic SCLC, therefore, probably should be treated as SCLC.
On the other hand, a bigger proportion of LCNEC tumors were classified as NSCLC-like tumors by either coalterations in TP53 plus RB1 or our extended criterion. While SCLC-PE and NSCLC-PEM demonstrated similar efficacy in these patients (Figs. 3 and 4), NSCLC-TAX/GEM appeared to be inferior to SCLC-PE or NSCLC-PEM. NSCLC-TAX/GEM is commonly used for NSCLC, particularly squamous cell carcinoma and sometimes in SCLC. In a previous study (11), Derks and colleagues reported that patients with wild-type RB1 treated with NSCLC-TAX/GEM had a significantly longer OS than those treated with SCLC-PE, which is contrary to the findings in this study. Reanalysis of our data was based solely on the mutation status of RB1 as in Derks and colleagues’ study, SCLC-PE still outperformed NSCLC-GEM/TAX (Supplementary Table S8). The underlying reasons for such discrepancy between these two studies are not clear. Difference in patient clinical characteristics, ethnicity, or concomitant therapy like radiation etc. could be potential factors that have contributed to the difference. However, because the sample size was small in both Derks and colleagues’ study (15 and 13 patients with RB1 wild-type LCNEC treated with NSCLC-GEM/TAX or SCLC-PE, respectively) and this study (11 and 17 patients with RB1 wild-type LCNEC treated with NSCLC-GEM/TAX or SCLC-PE, respectively), these data should be interpreted with extreme caution. Future studies with large sample size are needed to address this critical question.
Overall, SCLC-PE appeared to be a “good regimen” for the majority of patients with LCNEC, both SCLC-like and NSCLC-like in our cohort by either three therapeutic subgroups (Figs. 3 and 4) or by two therapeutic subgroups (Supplementary Fig. S2), consistent with multiple previous studies (8–10, 35). However, NSCLC regimens are still worth investigating, particularly in future studies with larger cohorts considering potentially different efficacy and toxicity profiles associated with different regimens. For example, in our study, although the difference did not reach statistical significance (P = 0.07), likely due to small sample size, some NSCLC-like LCNEC based on criterion 2, may have had better or comparable clinical benefit from pemetrexed-platinum (Figs. 3 and 4). As such, larger NGS panels when available should be considered to allow further classification of LCNEC to identify subgroup of patients who may benefit from different NSCLC regimens.
A disappointing fact, however, is how poor these patients with advanced LCNEC did no matter which chemotherapy regimen was used in our study and others (11). Therefore, a new paradigm in treating these patients is needed. Immune checkpoint inhibitors (ICI) have changed the therapeutic landscape of many cancer types (36–38). Encouraging data have emerged on the efficacy of ICIs in patients with advanced LCNEC (39, 40). However, our knowledge for ICIs in LCNEC is rudimentary as very few patients with LCNEC were included in prospective immunotherapy trials (36, 41) and the data on predictive biomarkers to ICIs in patients with LCNEC is sparse. Among promising predictive biomarkers to ICIs established in other cancer types (38, 42–45), PD-L1 and TMB were most scrutinized. There were case reports on durable response to ICIs in LCNEC with low PD-L1, but high TMB (40, 46). Given, high TMB was reported to be independent of PD-L1 and associated with benefit across multiple cancer types including both NSCLC and SCLC, it is not unreasonable to speculate that TMB may be predictive to ICIs in both SCLC-like and NSCLC-like LCNEC. To address these critical questions regarding the clinical benefit from ICIs in patients with LCNEC and optimal predictive biomarkers, prospective studies on larger cohort of patients are eventually warranted. Although an integrative approach should be applied to understand the mechanisms underlying response or resistance to ICIs in patients with LCNEC, NGS using large gene panels that cover critical cancer gene mutations and are able to accurately estimate TMB should be considered for correlative studies not only because genomic features could have profound impact on response to ICIs, but also because genomic alterations are potential optimal biomarkers, thanks to the facts that DNA is stable and technologies for DNA analyses are relatively mature. With these wealthy data from these studies, the impact of genomic subtyping on response to ICIs in patients with LCNEC can be further studied.
Disclosure of Potential Conflicts of Interest
S.G. Swisher is an employee/paid consultant for Peter MacCallum, reports receiving speakers bureau honoraria from the University of Louisville, IASLC, Oregon Health Science University, and West Hawaii Cancer Symposium, and is an advisory board member/unpaid consultant for Ethicon Inc. J.V. Heymach is an employee/paid consultant for University of Texas/MD Anderson Cancer Center, AstraZeneca, Boehringer-Ingelheim, Exelixis, Genentech, GlaxoSmithKline, Guardant Health, Henrgui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Takeda, Sanofi US Services, Roche, and Foundation Medicine, reports receiving commercial research grants from AstraZeneca, Bayer, GlaxoSmithKline, Spectrum, and Checkmate Pharmaceuticals, and receives royalties and licensing from Spectrum, and licensing from Bio-Tree Systems, Inc. P.A. Futreal is an employee/paid consultant for GenePlus. J. Zhang is an employee/paid consultant for Geneplus Institute-Beijing and AstraZeneca, reports receiving commercial research grants from Merck, and reports receiving speakers bureau honoraria from Roche, Innovent, Bristol-Myers Squibb, Origmed, and Geneplus. No potential conflicts of interest were disclosed by the other authors.
Conception and design: M. Zhuo, X. Yang, Yuyan Wang, J.V. Heymach, N. Kalhor, X. Xia, J. Zhang, J. Zhao
Development of methodology: M. Zhuo, Y. Guan, Yuqi Wang, H.A. Abbas, W. Chen, L. Yang, X. Yi
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Zhuo, X. Yang, L. Hong, R. Chen, J. Zhong, J. Li, M. Wu, W. Rinsurongkawong, S.G. Swisher, J.V. Heymach, I.I. Wistuba, N. Kalhor, B.S. Glisson
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Zhuo, Y. Guan, L. Hong, R. Chen, H.A. Abbas, L. Chang, Y. Gong, J. Zhong, W. Chen, X. Zhu, J. Wang, J.J. Lee, P.A. Futreal, J. Zhang, J. Zhao
Writing, review, and/or revision of the manuscript: M. Zhuo, Y. Guan, X. Yang, L. Hong, R. Chen, H.A. Abbas, X. Zhu, T. An, Z. Wang, E.B. Roarty, J.A. Roth, S.G. Swisher, J.J. Lee, J.V. Heymach, P.A. Futreal, B.S. Glisson, X. Xia, J. Zhang, J. Zhao
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Guan, Z. Li, H. Chen, Z. Dong, X. Zhu, Yuyan Wang, E.B. Roarty, J. Lewis, L. Yang, J. Zhao
Study supervision: M. Zhuo, N. Wu, X. Xia, J. Zhao
We are grateful to Dr. Ke Wang, Tao Liu, and Yanyan Zhang from Geneplus-Beijing Institute for their help with data analysis and statistics. We also appreciate support from the neuroendocrine carcinoma and neuroendocrine tumor multidiscipline team of Peking University Cancer Hospital and Institute. This study was supported by National Key R&D Program of China (grant no. 2018YFC0910700); the generous philanthropic contributions from The University of Texas MD Anderson Lung Moon Shot Program and the MD Anderson Cancer Center Support Grant (P30 CA01667); Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award grant (RP160668), the Cancer Prevention and Research Institute of Texas (R120501), the MD Anderson Physician Scientist Program, the Khalifa Scholar Award, the UT Lung Specialized Programs of Research Excellence Grant (P50CA70907), the T.J. Martell Foundation, the Beijing Natural Science Foundation (Commission No. 7162038), and the Beijing Municipal Administration of Hospitals’ Youth Program (Commission No. QML20161101).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.